N-glycan biosignatures as a potential diagnostic biomarker for early-stage pancreatic cancer

doi:10.4251/wjgo.v16.i3.659

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 3

This Article

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4408)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-5) series, Tables (1-5) series.

Item

Count

PDF

156

WORD

HTML

1934

Figures (1-5)

415

Tables (1-5)

446

Sum=2956

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

206

Download

1038

Sum=1244

Mar 15, 2024 (publication date) through Mar 2, 2026

Times Cited of This Article

Times Cited (7)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Case Control Study

World J Gastrointest Oncol. Mar 15, 2024; 16(3): 659-669
Published online Mar 15, 2024. doi: 10.4251/wjgo.v16.i3.659

N-glycan biosignatures as a potential diagnostic biomarker for early-stage pancreatic cancer

Yan-Rong Wen, Xia-Wen Lin, Yu-Wen Zhou, Lei Xu, Jun-Li Zhang, Cui-Ying Chen, Jian He

Yan-Rong Wen, Xia-Wen Lin, Jian He, Department of Nuclear Medicine, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing 210008, Jiangsu Province, China

Yu-Wen Zhou, Lei Xu, Jun-Li Zhang, Cui-Ying Chen, Department of Research and Development, Sysdiagno (Nanjing) Biotech Co., Ltd, Nanjing 210008, Jiangsu Province, China

Co-first authors: Yan-Rong Wen and Xia-Wen Lin.

Co-corresponding authors: Cui-Ying Chen and Jian He.

Author contributions: All authors contributed to the study conception and design. Wen YR and Lin XW contributed equally to this work; Lin XW and He J collected the samples and conducted the data analysis; Zhou YW, Xu L, Zhang JL, and Chen CY performed N-glycans analysis; Wen YR and He J designed the research, analyzed data and wrote the manuscript. He J and Chen CY are the co-corresponding authors of this study. He J and Chen CY were involved in the experimental design and revision of the article. Specifically, He J assumed responsibility for the overall design of the subject, Chen CY focused on the experimental design of the N-glycan analysis.

Supported by fundings for Clinical Trials from the Affiliated Drum Tower Hospital, Medical School of Nanjing University, No. 2021-LCYJ-MS-11.

Institutional review board statement: The study protocol was approved by the Ethics Committee of Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School and conformed to the ethical guidelines of the Declaration of Helsinki.

Informed consent statement: Written informed consent was obtained from all patients.

Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.

Data sharing statement: Technical appendix, statistical code, and dataset available from the corresponding author at hjxueren@126.com.

STROBE statement: The authors have read the STROBE Statement-checklist of items, and the manuscript was prepared and revised according to the STROBE Statement-checklist of items.

Corresponding author: Jian He, Doctor, PhD, Chief Doctor, Department of Nuclear Medicine, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, No. 321 Zhongshan Road, Nanjing 210008, Jiangsu Province, China. hjxueren@126.com

Received: October 5, 2023
Peer-review started: October 5, 2023
First decision: December 6, 2023
Revised: December 21, 2023
Accepted: January 18, 2024
Article in press: January 18, 2024
Published online: March 15, 2024
Processing time: 159 Days and 5.9 Hours

ARTICLE HIGHLIGHTS

Research background

The absence of diagnostic biomarkers for pancreatic cancer (PC) poses challenges in achieving early detection.

Research motivation

The aim of this study is to identify novel diagnostic markers for the early detection of PC.

Research objectives

The identification of novel glycan markers holds the potential to differentiate early-stage PC, while the development of corresponding models can facilitate the early diagnosis of PC as well as other pancreatic ailments.

Research methods

Serum N-glycan analysis performed to identify the serum biomarker signatures associated with early-stage pancreatic ductal adenocarcinoma (PDAC). A multivariate logistic regression analysis was performed to build a diagnostic model.

Research results

The biomarker signature was created to discriminate samples derived from patients with PC from those of controls. Glyco-model demonstrated favorable diagnostic performance in all stages of PC.

Research conclusions

The serum N-glycan biosignatures and the “Glyco-model” offer a viable method for detecting early-stage PDAC.

Research perspectives

There is a desire to develop additional biomarkers that exhibit heightened sensitivity and specificity for PDAC, in order to facilitate early detection.